PMEF
RNAM

Point72 Middle East FZE’s Avidity Biosciences RNAM Stock Holding History

Point72 Middle East FZE’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-5,792
Closed -$37K – 1821
2023
Q3 		$37K Buy
+5,792
New +$49.9K ﹤0.01% 1262

Other funds holding RNAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Point72 Middle East FZE's RNAM Position: Q4 2023 in Review

Point72 Middle East FZE sold out of Avidity Biosciences (RNAM) in Q4 2023, closing a stake of 5,792 shares — an estimated $37K sold.

Point72 Middle East FZE first reported a position in RNAM in Q3 2023 and held it in 1 quarter. The position peaked at $37K in Q3 2023. 144 funds tracked by Wall St. Rank hold RNAM as of Q4 2023.

  • Point72 Middle East FZE reported no remaining Avidity Biosciences position as of Q4 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 5,792 Avidity Biosciences shares in Q4 2023, an estimated $37K.
  • Point72 Middle East FZE first reported a position in Avidity Biosciences in Q3 2023 and held it in 1 quarter.
  • Point72 Middle East FZE's Avidity Biosciences position peaked at $37K in Q3 2023.
  • 144 funds tracked by Wall St. Rank held Avidity Biosciences as of Q4 2023.

Based on Point72 Middle East FZE's 13F filing for Q4 2023, filed 14 Feb 2024.